Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate

Philip N Sambrook, Christian Roux, Jean-Pierre Devogelaer, Kenneth Saag, Chak-Sing Lau, Jean-Yves Reginster, Christina Bucci-Rechtweg, Guoqin Su, David M Reid

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

We studied 265 men (mean age 56.4 years; range 18-83 years), among patients enrolled in two arms of a double-blind, 1-year study comparing the effects of zoledronic acid (ZOL) with risedronate (RIS) in patients either commencing (prednisolone 7.5 mg/day or equivalent) (prevention arm, n=88) or continuing glucocorticoid therapy (treatment arm, n=177).
Original languageEnglish
Pages (from-to)289-295
Number of pages7
JournalBone
Volume50
Issue number1
DOIs
Publication statusPublished - Jan 2012

Fingerprint Dive into the research topics of 'Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate'. Together they form a unique fingerprint.

  • Cite this

    Sambrook, P. N., Roux, C., Devogelaer, J-P., Saag, K., Lau, C-S., Reginster, J-Y., Bucci-Rechtweg, C., Su, G., & Reid, D. M. (2012). Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. Bone, 50(1), 289-295. https://doi.org/10.1016/j.bone.2011.10.024, https://doi.org/10.1016/j.bone.2011.12.006